C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 92 filers reported holding C4 THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 1.52 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $33,000 | -83.0% | 7,058 | -70.4% | 0.00% | – |
| Q1 2024 | $194,000 | +6366.7% | 23,850 | +4292.3% | 0.00% | – |
| Q4 2023 | $3,000 | -72.7% | 543 | -90.6% | 0.00% | – |
| Q3 2023 | $11,000 | +1000.0% | 5,804 | +936.4% | 0.00% | – |
| Q2 2023 | $1,000 | -88.9% | 560 | -80.9% | 0.00% | – |
| Q1 2023 | $9,000 | -81.6% | 2,933 | -64.6% | 0.00% | – |
| Q4 2022 | $49,000 | +444.4% | 8,286 | +683.9% | 0.00% | – |
| Q3 2022 | $9,000 | +50.0% | 1,057 | +35.5% | 0.00% | – |
| Q2 2022 | $6,000 | -90.0% | 780 | -68.2% | 0.00% | – |
| Q1 2022 | $60,000 | -83.7% | 2,456 | -78.6% | 0.00% | – |
| Q4 2021 | $369,000 | +8.2% | 11,475 | +50.5% | 0.00% | – |
| Q3 2021 | $341,000 | +74.0% | 7,625 | +47.3% | 0.00% | – |
| Q2 2021 | $196,000 | +493.9% | 5,177 | +472.0% | 0.00% | – |
| Q1 2021 | $33,000 | -2.9% | 905 | -11.5% | 0.00% | – |
| Q4 2020 | $34,000 | – | 1,023 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 6,880,527 | $31,788,035 | 11.47% |
| Soleus Capital Management, L.P. | 4,051,996 | $18,720,222 | 1.65% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,442,841 | $6,665,925 | 1.57% |
| COMMODORE CAPITAL LP | 3,410,384 | $15,755,974 | 1.08% |
| TCG Crossover Management, LLC | 1,276,574 | $5,897,772 | 0.62% |
| Bain Capital Life Sciences Investors, LLC | 1,111,910 | $5,137,024 | 0.56% |
| RA Capital Management | 4,878,000 | $22,536,360 | 0.30% |
| Atom Investors LP | 332,620 | $1,536,704 | 0.15% |
| Orbimed Advisors | 1,513,058 | $6,990,328 | 0.14% |
| WASATCH ADVISORS LP | 4,847,150 | $22,393,833 | 0.12% |